Category Archives: Guest Blog

Patent Filing to Drug Approval: A Difficult Journey Even for the Mighty

By Guest Blogger | Published: March 20, 2012
By Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit. The UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years. According to the law firm, only 129 “patent families” [...]
Also posted in Global | Tagged , , | 1 Comment

AZ's Seroquel Battle with FDA: A Mark of Desperation?

By Guest Blogger | Published: March 14, 2012
By Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit. Is it a mark of desperation? UK-based pharma company AstraZeneca has resorted to suing the US Food and Drug Administration in a bid to stop it from approving generic competition to Seroquel, the company’s blockbuster anti-depressant, before December 2012. The core patent for Seroquel IR expired in September [...]
Posted in Guest Blog | Tagged , , , | 3 Comments

Mastering Medical Animation

By Guest Blogger | Published: March 9, 2012
By Jane Hurd, President, The Association of Medical Illustrators We thank you and your editorial staff for publishing the article titled ‘How to Choose a Medical Animator’ in the 1 February issue of Pharmaceutical Executive. This is a common industry challenge — choosing a qualified, knowledgeable, and trustworthy media partner in what is a significant asset [...]
Posted in Guest Blog | Tagged , | Leave a comment

VC Funding Floods Colorado Biotechs, But Will It Stifle Innovation?

By Guest Blogger | Published: March 5, 2012
By Marylyn Donahue. Biotechs in Colorado, US, are enjoying a windfall of funding from Venture Capitalists who have to date invested $66.1 million in six of the state’s companies working in the fields of biofuel, medical devices and biopharma, according to a report released Feb 21 by OnBioVC, a Boulder-based tracker of investments in the life [...]
Also posted in Biotech, Deals | Tagged , , , , , , , | Leave a comment

Pharma's Chaos Scenario: Why the Old Commercial Model Just Won't Cut It

By Guest Blogger | Published: March 2, 2012
By Peter Houston, Director of Content, Advanstar Communications. A couple of years ago I spoke at a Life Sciences Forum organized by Oracle. The audience was 100-percent life science and IT professionals, but I spoke about the magazine business. Why? Cynics say because I don’t know enough about science or IT, but really it was more [...]
Also posted in Technology, social media | Tagged , , | Leave a comment